Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Heart Failure

Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

JAMA Cardiol

Cunningham JW, Chatur S, Claggett BL, Vaduganathan M, Desai AS, Jhund PS, Llamas Esperón G, Lam CSP, Sato N, Senni M, Shah S, Voors A, Zannad F, Pitt B, Zieroth S, Brinker M, Rohwedder K, Kim SY, Lay-Flurrie J, Viswanathan P, McMurray JJV, Solomon SD

doi: 10.1001/jamacardio.2025.0016

Heart Failure

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial

JAMA Cardiol

Desai AS, Jhund PS, Vaduganathan M, Claggett BL, Cunningham JW, Pabon MA, Lam CSP, Senni M, Shah S, Voors AA, Zannad F, Pitt B, Amarante F, Lay-Flurrie J, Scheerer MF, Lage A, McMurray JJV, Solomon SD

doi: 10.1001/jamacardio.2025.0860

Heart Failure

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Eur J Heart Fail

Butt JH, Jhund PS, Henderson AD, Claggett BL, Desai AS, Lam CSP, Mueller K, Scheerer MF, Viswanathan P, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV

doi: 10.1002/ejhf.3661

Heart Failure

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Eur J Heart Fail

Malgie J, Wilde MI, Koudstaal S, Denham R, da Fonseca CA, Swart HP, van Ofwegen CEE, Yilmaz A, Pisters R, Linssen GCM, Faber N, van Heerebeek L, van de Swaluw JEC, de Boer RA, Brunner-La Rocca HP, Brugts JJ

doi: 10.1002/ejhf.70006

COMMENTED

Heart Failure

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Lancet Diabetes Endocrinol

Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators

doi: 10.1016/S2213-8587(24)00304-8

Heart Failure

In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial

J Am Heart Assoc

Nouhravesh N, Cyr D, Hernandez AF, Morrow DA, Velazquez EJ, Ward J, Sarwat S, Sharma K, Williamson K, Starling RC, Lepage S, Zieroth S, Solomon SD, Mentz RJ

doi: 10.1161/JAHA.124.037899

Heart Failure

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

PLoS One

Bitos K, Laptseva N, Haider T, Rossi VA, Nägele MP, Barthelmes J, Ruschitzka F, Sudano I, Flammer AJ

doi: 10.1371/journal.pone.0325668

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

Heart Failure

Structural Abnormalities and Effects of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: The PARAGLIDE-HF Trial

Am Heart J

Kittipibul V, Cyr DD, Harrington J, Lala A, Fudim M, Ward JH, Sarwat S, Solomon SD, Hernandez AF, Zieroth S, Starling RC, Mentz RJ

doi: 10.1016/j.ahj.2025.05.004

Related content

Finerenone and Outpatient Worsening Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial

Mode of Death in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial

Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

In-Hospital or Out-of-Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE-HF Trial

Effects of dapagliflozin on blood volume status and vascular outcomes in clinically stabilized heart failure patients after an acute decompensated heart failure event (DAPA-VOLVO study): Protocol of a double-blind randomized controlled clinical trial

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Structural Abnormalities and Effects of Sacubitril/Valsartan in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure: The PARAGLIDE-HF Trial